Publications:

A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering.

Molecular Therapy Oncolytics

Liu, Ximing X; Tian, Xinxin X; Hao, Xinyan X; Zhang, Huixiang H; Wang, Kailun K; Wei, Zhizhong Z; Wei, Xin X; Li, Yulu Y; Sui, Jianhua J

Publication Date: 2022-12-15

Variant appearance in text: EGFR: H433A

PubMed Link: 36458200

Variant Present in the following documents:

• Main text
• mmc2.pdf
• main.pdf

View BVdb publication page

Antibody Structure and Function: The Basis for Engineering Therapeutics.

Antibodies (Basel, Switzerland)

Chiu, Mark L ML; Goulet, Dennis R DR; Teplyakov, Alexey A; Gilliland, Gary L GL

Publication Date: 2019-12-03

Variant appearance in text: EGFR: H433A

PubMed Link: 31816964

Variant Present in the following documents:

• Main text

View BVdb publication page

TRIM21-From Intracellular Immunity to Therapy.

Frontiers In Immunology

Foss, Stian S; Bottermann, Maria M; Jonsson, Alexandra A; Sandlie, Inger I; James, Leo C LC; Andersen, Jan Terje JT

Publication Date: 2019

Variant appearance in text: EGFR: H433A

PubMed Link: 31555278

Variant Present in the following documents:

• Main text
• fimmu-10-02049.pdf

View BVdb publication page